Physician profile
James E Nininger
NPI 1235298530
$7,140.70
in general payments reported to CMS, 2019-2025
11 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $949 · 2021: $871 · 2022: $1,633 · 2023: $1,313 · 2024: $568 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,772.44 | 2021-2023 | |
| Allergan, INC. | $1,556.95 | 2019-2020 | |
| Lundbeck LLC | $765.24 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $684.29 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $631.39 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $625.01 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $405.80 | 2022-2025 | Lybalvi |
| Sunovion Pharmaceuticals INC. | $303.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $152.34 | 2023 | Uzedy |
| Janssen Pharmaceuticals, INC | $123.50 | 2019 | |
| Pfizer INC. | $120.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Nininger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.